IL139211A0 - New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol - Google Patents

New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol

Info

Publication number
IL139211A0
IL139211A0 IL13921199A IL13921199A IL139211A0 IL 139211 A0 IL139211 A0 IL 139211A0 IL 13921199 A IL13921199 A IL 13921199A IL 13921199 A IL13921199 A IL 13921199A IL 139211 A0 IL139211 A0 IL 139211A0
Authority
IL
Israel
Prior art keywords
pindolol
reboxetine
disorders
new drug
drug combinations
Prior art date
Application number
IL13921199A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of IL139211A0 publication Critical patent/IL139211A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL13921199A 1998-05-08 1999-04-14 New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol IL139211A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8486098P 1998-05-08 1998-05-08
PCT/US1999/006523 WO1999058130A1 (en) 1998-05-08 1999-04-14 New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol

Publications (1)

Publication Number Publication Date
IL139211A0 true IL139211A0 (en) 2001-11-25

Family

ID=22187677

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13921199A IL139211A0 (en) 1998-05-08 1999-04-14 New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol

Country Status (22)

Country Link
EP (1) EP1075264B1 (ko)
JP (1) JP2002514601A (ko)
KR (1) KR20010052319A (ko)
CN (1) CN1300217A (ko)
AT (1) ATE283694T1 (ko)
AU (1) AU764579B2 (ko)
BR (1) BR9909559A (ko)
CA (1) CA2326105A1 (ko)
DE (1) DE69922367T2 (ko)
EA (1) EA003469B1 (ko)
ES (1) ES2232128T3 (ko)
HU (1) HUP0101341A3 (ko)
IL (1) IL139211A0 (ko)
NO (1) NO20005621D0 (ko)
NZ (1) NZ508035A (ko)
PL (1) PL345351A1 (ko)
PT (1) PT1075264E (ko)
SI (1) SI1075264T1 (ko)
SK (1) SK14502000A3 (ko)
TR (1) TR200003262T2 (ko)
WO (1) WO1999058130A1 (ko)
ZA (1) ZA200005301B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1500395B1 (en) * 1999-07-01 2006-03-08 Pharmacia & Upjohn Company LLC Reboxetine for treating fibromyalgia and other somatoform disorders
PT1632234E (pt) 1999-07-01 2007-07-09 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para o tratamento da síndrome de fadiga crónica
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
EP1723957A3 (en) 2002-12-27 2013-01-23 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
EP2429514A1 (en) * 2009-05-13 2012-03-21 Sunovion Pharmaceuticals Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/ antagonists and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ES2145977T3 (es) * 1995-08-16 2000-07-16 Lilly Co Eli Potenciacion de la respuesta de la serotonina.

Also Published As

Publication number Publication date
BR9909559A (pt) 2000-12-19
EA003469B1 (ru) 2003-06-26
ATE283694T1 (de) 2004-12-15
WO1999058130A1 (en) 1999-11-18
EP1075264A1 (en) 2001-02-14
JP2002514601A (ja) 2002-05-21
HUP0101341A2 (hu) 2001-08-28
CN1300217A (zh) 2001-06-20
PL345351A1 (en) 2001-12-17
AU764579B2 (en) 2003-08-21
NO20005621L (no) 2000-11-07
SI1075264T1 (en) 2005-06-30
AU3546099A (en) 1999-11-29
KR20010052319A (ko) 2001-06-25
PT1075264E (pt) 2005-01-31
EA200001162A1 (ru) 2001-04-23
ZA200005301B (en) 2001-10-01
DE69922367D1 (de) 2005-01-05
HUP0101341A3 (en) 2006-07-28
DE69922367T2 (de) 2005-12-22
ES2232128T3 (es) 2005-05-16
CA2326105A1 (en) 1999-11-18
SK14502000A3 (sk) 2001-05-10
EP1075264B1 (en) 2004-12-01
NZ508035A (en) 2004-02-27
TR200003262T2 (tr) 2001-03-21
NO20005621D0 (no) 2000-11-07

Similar Documents

Publication Publication Date Title
RS20120158A3 (en) Phenyl-piperazine Derivatives As Serotonin Resorption Inhibitors
DE60020613D1 (de) (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
EE200100441A (et) Monoamiinide taasomastamise inhibiitorid kesknärvisüsteemi haiguste raviks
HK1089177A1 (en) Modulators of peripheral 5-ht receptors
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
PL345351A1 (en) New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol
NO20070914L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
ATE424825T1 (de) Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
BRPI0511529A (pt) combinação terapêutica para distúrbios de hiperatividade/déficit de atenção
MY136367A (en) Treatment of cognitive failure
YU89103A (sh) Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a
WO2002040006A3 (en) Treatment of anxiety disorders
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
NO20085172L (no) 3-(1h-indol-3-yl)indan-1-ylaminderivater for behandlingen av depresjon og angst
HK1056120A1 (en) Use of quetiapine for attention deficit hyperactivity disorder or conduct disorder.
HUP0101748A2 (hu) Reboxetin alkalmazása idegrendszeri zavarok kezelésére szolgáló gyógyszerkészítmények előállítására
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
UA83017C2 (uk) Комбінація рофлуміласту та r,r-формотеролу для лікування захворювань дихальних шляхів
UA85198C2 (ru) Производные морфолина как ингибиторы повторного поглощения норэпинефрина
PT1282414E (pt) Compostos derivados de felbamato para o tratamento da dor neuropatica
BR9803615A (pt) Dispositivo amortecedor de ruìdos para discos diamantados

Legal Events

Date Code Title Description
MM9K Patent not in force due to non-payment of renewal fees